OP0078 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-WEEK) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials - Concepedia

Concepedia

Publication | Closed Access

OP0078 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-WEEK) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials

12

Citations

0

References

2014

Year

Arthur Kavanaugh, Maurizio Cutolo, P. J. Mease, Dafna D. Gladman, Ade Adebajo, Juan J. Gómez‐Reino, J. Wollenhaupt, Georg Schett, Éric Lespessailles, C. Hu,

Annals of the Rheumatic Diseases

No additional data available for this publication yet. Check back later!